Published: Tue, November 14, 2017
Medicine | By Earnest Bishop

FDA Approves First Pill That Tracks If You've Swallowed It

FDA Approves First Pill That Tracks If You've Swallowed It

Forgetfulness and cloudy thinking can be symptoms of the mental health conditions that Abilify is approved to treat, and patients with mental illness are known to struggle to take medication consistently. It can also be used in the acute treatment of manic and mixed episodes associated with bipolar I disorder so it has the potential to do a whole lot of good.

In a statement on Monday, the FDA said that the digitally-enhanced drug "works by sending a message from the pill's sensor to a wearable patch". A web-based portal is also available to give physicians and caregivers access to the data, as allowed by a patient.

In combination though, the Abilify MyCite system was rejected by the FDA in April past year due to concerns over the possible impact of "human factors" on safety.

The pill should not be used to track digestion in "real time" or during an emergency, as detection could be delayed or faulty, the FDA warned.

Applying technology directly into the medicines themselves is a more cutting-edge approach, but one that is clearly gaining traction, as evidenced by the FDA's approval of Abilify MyCite (aripiprazole tablets with sensor). The tracking system tracks ingestion of the medication, activity levels, and sleep patterns, as well as self-reported rest and mood which, with patient consent, can be shared with the healthcare provider and selected members of the family and care team.

Rosogolla originated in West Bengal not Odisha stamps Geographical Indication
The Odisha government responded by ordering the formation of three committees to settle the dispute over rosogulla's origins. It was a day of celebration at "Rosogolla Bhawan", the family home of Nabin Chandra Das, the inventor of Rosogolla.

Would you ingest a digital pill that allows you to conveniently track when you took the medication - and possibly allow others to track it as well?

The FDA accepted the Otsuka-Proteus new drug application for review in September 2015.

Although the sensor can alert caregivers, the makers of Abilify, Japan-based Otsuka Pharmaceutical, said it is unclear whether the tracking device will actually help improve patients' ability to take their medication daily as prescribed.

The companies said the Proteus Ingestible sensor "activates when it reaches stomach fluids and communicates with the patch". In the drug's label, for instance, the FDA noted the wearable patch detects the IEM signal usually within 30 minutes following ingestion.

"Being able to track ingestion of medications prescribed for mental illness may be useful for some patients", Mitchell Mathis, MD, director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, said in a statement. The system is meant to integrate into individuals' lives, and individuals indicate through the app which member (s) of their care team can access information about their medication ingestion, activity, and self-reported mood and rest.

Like this: